MEPO promotes neurogenesis and angiogenesis but suppresses gliogenesis in mice with acute ischemic stroke
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Pharmacology"
DOI: 10.1016/j.ejphar.2019.01.066
Abstract: &NA; Previously study has proved the non‐erythropoietic mutant erythropoietin (MEPO) exerted neuroprotective effects against ischemic cerebral injury, with an efficacy similar to that of wild‐type EPO. This study investigates its effects on neurogenesis, angiogenesis, and… read more here.
Keywords: ischemic stroke; gliogenesis; mice; neurogenesis angiogenesis ... See more keywords
FRI0278 OFF-LABEL USE OF BIOLOGICAL THERAPIES IN RELAPSING AND/OR REFRACTORY EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.6243
Abstract: Background: Eosinophilic granulomatosis with polyangiitis (EGPA), formerly named Churg-Strauss syndrome, is a small-vessel necrotizing vasculitis associated with eosinophilia and asthma. Glucocorticoids (GCs) usually control the disease, but relapses and GC-dependant asthma are frequent, leading to… read more here.
Keywords: none; none declared; use; mepo ... See more keywords
OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.5544
Abstract: Background: Evidence on the efficacy of Mepolizumab (MEPO) in Eosinophilic Granulomatosis with Polyangiitis (EGPA) is scarce [1]. Objectives: To assess the efficacy and safety of MEPO in real-life clinical practice. Methods: We retrospectively included patients… read more here.
Keywords: none; none declared; mepo; granulomatosis polyangiitis ... See more keywords
Mepolizumab in patients ≥3 exacerbations and eosinophil count ≥300 cells/µL
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.pa3958
Abstract: Rationale: The PH3 mepolizumab (mepo) MENSA (M) study included patients (pt) with a history of ≥2 exacerbations in the year (yr) preceding randomization, receiving high dose ICS + ≥1 additional asthma controller, and blood eosinophils… read more here.
Keywords: sub pop; pbo; rate; mepo ... See more keywords